Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C. Gelu-Simeon, M., Burlaud, A., Young, J., Pelletier, G., & Buffet, C. World J Gastroenterol, 15(3):328–33, January, 2009.
abstract   bibtex   
AIM: To study predictive factors of thyroid dysfunction associated with interferon-alpha (IFNalpha) therapy in chronic hepatitis C (CHC) and to describe its long-term evolution in a large population without previous thyroid dysfunction. METHODS: We performed a follow-up of thyroid function and detection of thyroid antibodies in 301 patients treated for CHC with IFNalpha from 1999 to 2004. RESULTS: Thyroid disorder developed in 30/301 (10%) patients with a mean delay of 6 +/- 3.75 mo: 13 patients had hyperthyroidism, 11 had hypothyroidism, and 6 had biphasic evolution. During a mean follow-up of 41.59 +/- 15.39 mo, 9 patients with hyperthyroidism, 3 with hypothyroidism, and 4 with biphasic evolution normalized thyroid function in 7.88 +/- 5.46 mo. Recovery rate of dysthyroidism was not modified by treatment discontinuation, but was better for patients with negative thyroid antibodies before antiviral treatment (P = 0.02). Women had significantly more dysthyroidism (P = 0.05). Positive thyroid peroxidase and thyroglobulin antibodies were more frequent before antiviral treatment in patients who developed dysthyroidism (P \textless 0.0003 and P = 0.0003, respectively). In a multivariate model, low fibrosis was found to be a predictive factor of dysthyroidism (P = 0.039). CONCLUSION: In this monocentric population of CHC, dysthyroidism, especially hyperthyroidism, developed in 10% of patients. Low fibrosis was found to be a predictive factor of dysthyroidism. Thyroid disorder recovered in 16/30 patients (53%) and recovery was better in the non-autoimmune form.
@article{gelu-simeon_evolution_2009,
	title = {Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis {C}},
	volume = {15},
	issn = {1007-9327 (PRINT); 1007-9327 (LINKING)},
	shorttitle = {Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis {C}},
	abstract = {AIM: To study predictive factors of thyroid dysfunction associated with interferon-alpha (IFNalpha) therapy in chronic hepatitis C (CHC) and to describe its long-term evolution in a large population without previous thyroid dysfunction. METHODS: We performed a follow-up of thyroid function and detection of thyroid antibodies in 301 patients treated for CHC with IFNalpha from 1999 to 2004. RESULTS: Thyroid disorder developed in 30/301 (10\%) patients with a mean delay of 6 +/- 3.75 mo: 13 patients had hyperthyroidism, 11 had hypothyroidism, and 6 had biphasic evolution. During a mean follow-up of 41.59 +/- 15.39 mo, 9 patients with hyperthyroidism, 3 with hypothyroidism, and 4 with biphasic evolution normalized thyroid function in 7.88 +/- 5.46 mo. Recovery rate of dysthyroidism was not modified by treatment discontinuation, but was better for patients with negative thyroid antibodies before antiviral treatment (P = 0.02). Women had significantly more dysthyroidism (P = 0.05). Positive thyroid peroxidase and thyroglobulin antibodies were more frequent before antiviral treatment in patients who developed dysthyroidism (P {\textless} 0.0003 and P = 0.0003, respectively). In a multivariate model, low fibrosis was found to be a predictive factor of dysthyroidism (P = 0.039). CONCLUSION: In this monocentric population of CHC, dysthyroidism, especially hyperthyroidism, developed in 10\% of patients. Low fibrosis was found to be a predictive factor of dysthyroidism. Thyroid disorder recovered in 16/30 patients (53\%) and recovery was better in the non-autoimmune form.},
	number = {3},
	journal = {World J Gastroenterol},
	author = {Gelu-Simeon, M. and Burlaud, A. and Young, J. and Pelletier, G. and Buffet, C.},
	month = jan,
	year = {2009},
	keywords = {Adult, Aged, Agents/adverse, Antiviral, Autoantibodies/immunology, C/diagnosis/, Diseases/, Female, Fibrosis/pathology, Follow-Up, Hepatitis, Humans, Interferon-alpha/adverse, Male, Middle, Studies, Therapy, Thyroid, chemically, drug, effects/therapeutic, induced/classification/pathology, use},
	pages = {328--33},
}

Downloads: 0